As of Jan 20
| +0.17 / +1.52%|
The 8 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 9.50, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a -16.37% decrease from the last price of 11.36.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.